Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$468M |
| 2 |
Johnson & Johnson
JNJ
|
+$440M |
| 3 |
IBM
IBM
|
+$355M |
| 4 |
Booking.com
BKNG
|
+$332M |
| 5 |
RAI
Reynolds American Inc
RAI
|
+$331M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LLTC
Linear Technology Corp
LLTC
|
+$482M |
| 2 |
Walt Disney
DIS
|
+$247M |
| 3 |
Visa
V
|
+$219M |
| 4 |
Deere & Co
DE
|
+$200M |
| 5 |
Johnson Controls International
JCI
|
+$179M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.02% |
| 2 | Technology | 13.31% |
| 3 | Financials | 12.25% |
| 4 | Industrials | 9.65% |
| 5 | Consumer Staples | 9.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Newmont
NEM
$124B
| $20.8M | 0.03% |
630,540
-2,126,960
| -77% | -$74.3M |
|
|
AGU
777
DELISTED
Agrium
AGU
| $20.7M | 0.03% |
+217,088
| New | +$21.9M |
|
778
Novanta
NOVT
$6.32B
| $20.7M | 0.03% |
779,500
+55,300
| +8% | +$1.35M |
|
779
Grupo Aeroportuario del Sureste
ASR
$8.24B
| $20.7M | 0.03% |
119,400
-1,000
| -0.8% | -$155K |
|
|
GOV
780
DELISTED
Government Properties Income Trust
GOV
| $20.6M | 0.03% |
984,500
-89,900
| -8% | -$1.79M |
|
781
Regis Corp
RGS
$69.3M
| $20.6M | 0.03% |
87,875
+1,530
| +2% | +$399K |
|
782
Loews
L
$23.1B
| $20.5M | 0.03% |
439,100
-694,300
| -61% | -$32.5M |
|
|
AVTA
783
DELISTED
Avantax, Inc. Common Stock
AVTA
| $20.5M | 0.03% |
1,185,600
+82,900
| +8% | +$1.3M |
|
784
Seaboard Corp
SEB
$4.02B
| $20.5M | 0.03% |
4,906
-20
| -0.4% | -$78.2K |
|
785
Accuray
ARAY
$33.4M
| $20.5M | 0.03% |
4,305,600
+98,100
| +2% | +$511K |
|
|
SCLN
786
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
| $20.4M | 0.03% |
2,084,100
+314,202
| +18% | +$3.14M |
|
787
Emergent Biosolutions
EBS
$233M
| $20.4M | 0.03% |
702,711
-180,800
| -20% | -$5.5M |
|
788
Quaker Houghton
KWR
$2.91B
| $20.4M | 0.03% |
154,800
-30,600
| -17% | -$4M |
|
789
Corcept Therapeutics
CORT
$12.1B
| $20.4M | 0.03% |
1,858,500
+351,000
| +23% | +$3.08M |
|
790
First American
FAF
$7.38B
| $20.4M | 0.03% |
518,500
-21,262
| -4% | -$813K |
|
791
Invesco
IVZ
$13.9B
| $20.4M | 0.03% |
+664,700
| New | +$20.8M |
|
792
TriCo Bancshares
TCBK
$1.84B
| $20.4M | 0.03% |
573,037
-7,355
| -1% | -$261K |
|
|
STAY
793
DELISTED
Extended Stay America, Inc. Paired Share Unit
STAY
| $20.3M | 0.03% |
1,276,400
+643,800
| +102% | +$10.7M |
|
794
Expeditors International
EXPD
$24B
| $20.3M | 0.03% |
360,116
-215,000
| -37% | -$11.8M |
|
|
PRAH
795
DELISTED
PRA Health Sciences, Inc.
PRAH
| $20.3M | 0.03% |
+311,800
| New | +$18.4M |
|
796
A10 Networks
ATEN
$2B
| $20.3M | 0.03% |
2,220,700
+56,300
| +3% | +$498K |
|
|
TTSH
797
DELISTED
Tile Shop Holdings
TTSH
| $20.3M | 0.03% |
1,055,100
-115,300
| -10% | -$2.16M |
|
|
MBLY
798
DELISTED
Mobileye N.V.
MBLY
| $20.2M | 0.03% |
329,700
-199,600
| -38% | -$9.6M |
|
799
GoDaddy
GDDY
$11.6B
| $20.2M | 0.03% |
532,700
+410,600
| +336% | +$14.9M |
|
800
Acacia Research
ACTG
$455M
| $20.2M | 0.03% |
3,505,600
+103,800
| +3% | +$606K |
|
Similar funds
Jim Simons's Q1 2017 Portfolio in Review
As of Q1 2017, Jim Simons held 3,652 positions worth $71.6B, up 13% from $63.2B the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.
Jim Simons deployed $5.19B of net new capital in Q1 2017, opening 433 new positions and adding to 1,585 existing holdings. Its largest new stake was Merck: 7,716,460 shares worth $468M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 12% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Walt Disney, an estimated $247M trimmed.
- Jim Simons's largest Q1 2017 buy was Merck: 7,716,460 shares worth $468M.
- Jim Simons added most to Johnson & Johnson in Q1 2017, an estimated $440M increase.
- Jim Simons's biggest Q1 2017 reduction was Walt Disney, cutting an estimated $247M.
- Jim Simons fully exited Linear Technology Corp in Q1 2017, selling an estimated $482M.
- Jim Simons's ten largest holdings make up 7.9% of its $71.6B portfolio in Q1 2017.
- Jim Simons opened 433 new positions and closed 462 in Q1 2017.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $71.6B.
Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.